The anti-tumor effects of cordycepin-loaded liposomes on the growth of hepatoma 22 tumors in mice and human hepatoma BEL-7402 cells in culture

References

• Aramwit P, Porasuphatana S, Srichana T, Nakpheng T. Toxicity evaluation of cordycepin and its delivery system for sustained in vitro anti-lung cancer activity. Nanoscale Res Lett 2015;10:152.
   PubMed Web of Science ®Google Scholar
• Shi P, Huang Z, Tan X, Chen G. Proteomic detection of changes in protein expression induced by cordycepin in human hepatocellular carcinoma BEL-7402 cells. Methods Find Exp Clin Pharmacol 2008;30:347–53.
   PubMedGoogle Scholar
• Li G, Nakagome I, Hirono S, et al. Inhibition of adenosine deaminase (ADA)-mediated metabolism of cordycepin by natural substances. Pharmacol Res Perspect 2015;3:e00121.
   Google Scholar
• Chen Y, Chen YC, Lin YT, et al. Cordycepin induces apoptosis of CGTH W-2 thyroid carcinoma cells through the calcium-calpain-caspase 7-PARP pathway. J Agric Food Chem 2010;58:11645–52.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Shinozuka K, Yoshikawa N. Anticancer and antimetastatic effects of cordycepin, an active component of Cordyceps sinensis. J Pharmacol Sci 2015;127:53–6.
   PubMed Web of Science ®Google Scholar
• Primon-Barros M, Rigo GV, Frasson AP, et al. Modulatory effect of iron chelators on adenosine deaminase activity and gene expression in Trichomonas vaginalis. Mem Inst Oswaldo Cruz 2015;110:877–83.
   PubMed Web of Science ®Google Scholar
• Tuli HS, Sharma AK, Sandhu SS, Kashyap D. Cordycepin: a bioactive metabolite with therapeutic potential. Life Sci 2013;93:863–9.
   PubMed Web of Science ®Google Scholar
• Silver JN, Flotte TR. Towards a rAAV-based gene therapy for ADA-SCID: from ADA deficiency to current and future treatment strategies. Pharmacogenomics 2008;9:947–68.
   PubMed Web of Science ®Google Scholar
• Adams SP, Wilson M, Harb E, Fairbanks L, et al. Spectrum of mutations in a cohort of UK patients with ADA deficient SCID: segregation of genotypes with specific ethnicities. Clin Immunol 2015;161:174–9.
   PubMed Web of Science ®Google Scholar
• Da Silva AS, Wolkmer P, Nunes JT, et al. Susceptibility of Trypanosoma evansi to cordycepin. Biomed Pharmacother 2011;65:220–3.
   PubMed Web of Science ®Google Scholar
• Chapekar MS, Glazer RI. Cordycepin analog of (A2’p)2A: evidence that it functions as a prodrug of cordycepin. Biochem Biophys Res Commun 1983;115:137–43.
   PubMed Web of Science ®Google Scholar
• Qu C, Ni J, Yang P, et al. Altered plasma and brain disposition of isopropylidene shikimic acid liposome in rats and the brain protection in cerebral ischemia-reperfusion. Drug Dev Ind Pharm 2013;39:1291–5.
   PubMed Web of Science ®Google Scholar
• Lu XY, Hu S, Jin Y, Qiu LY. Application of liposome encapsulation technique to improve anti-carcinoma effect of resveratrol. Drug Dev Ind Pharm 2012;38:314–22.
   PubMed Web of Science ®Google Scholar
• Urbinati G, Marsaud V, Renoir JM. Anticancer drugs in liposomal nanodevices: a target delivery for a targeted therapy. Curr Top Med Chem 2012;12:1693–712.
   PubMed Web of Science ®Google Scholar
• Voinea M, Simionescu M. Designing of ‘intelligent’ liposomes for efficient delivery of drugs. J Cell Mol Med 2002;6:465–74.
   PubMed Web of Science ®Google Scholar
• Edwards SJ, Barton S, Thurgar E, Trevor N. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation. Health Technol Assess 2015;19:1–480.
   Web of Science ®Google Scholar
• Yarosh DB. Liposomes in investigative dermatology. Photodermatol Photoimmunol Photomed 2001;17:203–12.
   PubMed Web of Science ®Google Scholar
• Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomedicine 2015;10:975–99.
   PubMed Web of Science ®Google Scholar
• Li F, Yang R, Weng Y, Tang X. Preparation and evaluation of lyophilized liposome-encapsulated bufadienolides. Drug Dev Ind Pharm 2009;35:1048–58.
   PubMed Web of Science ®Google Scholar
• McGlynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2005;19:3–23.
   PubMed Web of Science ®Google Scholar
• Thomadaki H, Tsiapalis CM, Scorilas A. Polyadenylate polymerase modulations in human epithelioid cervix and breast cancer cell lines treated with etoposide or cordycepin, follow cell cycle rather than apoptosis induction. Biol Chem 2005;386:471–80.
   PubMed Web of Science ®Google Scholar
• Chen J, Lin A, Chen Z, et al. Ammonium sulfate gradient loading of brucine into liposomes: effect of phospholipid composition on entrapment efficiency and physicochemical properties in vitro. Drug Dev Ind Pharm 2010;36:245–53.
   PubMed Web of Science ®Google Scholar
• Islambulchilar Z, Ghanbarzadeh S, Emami S, et al. Development and validation of an HPLC method for the analysis of sirolimus in drug products. Adv Pharm Bull 2012;2:135–9.
   PubMedGoogle Scholar
• Shabbits JA1, Chiu GN, Mayer LD. Development of an in vitro drug release assay that accurately predicts in vivo drug retention for liposome-based delivery systems. J Control Release 2002;84:161–70.
   PubMed Web of Science ®Google Scholar
• Han BJ, Li W, Jiang GB, et al. Effects of daidzein in regards to cytotoxicity in vitro, apoptosis, reactive oxygen species level, cell cycle arrest and the expression of caspase and Bcl-2 family proteins. Oncol Rep 2015;34:1115–20.
   PubMed Web of Science ®Google Scholar
• Nikpoor AR, Tavakkol-Afshari J, Gholizadeh Z, et al. Nanoliposome-mediated targeting of antibodies to tumors: IVIG antibodies as a model. Int J Pharm 2015;495:162–70.
   PubMed Web of Science ®Google Scholar
• Li H, Guo K, Wu C, et al. Controlled and targeted drug delivery by a UV-responsive liposome for overcoming chemo-resistance in non-Hodgkin lymphoma. Chem Biol Drug Des 2015;86:783–94.
   PubMed Web of Science ®Google Scholar
• Ocal H, Arica-Yegin B, Vural I, et al. 5-Fluorouracil-loaded PLA/PLGA PEG-PPG-PEG polymeric nanoparticles: formulation, in vitro characterization and cell culture studies. Drug Dev Ind Pharm 2014;40:560–7.
   PubMed Web of Science ®Google Scholar
• Xiao-yun Z, Jing-man N, Hua Q. Study on the stability of podophyllotoxin liposome. Chin J Biochem Pharm 2006;27:141–4. [In Chinese]
   Google Scholar
• Vodnala SK, Lundbäck T, Yeheskieli E, et al. Structure-activity relationships of synthetic cordycepin analogues as experimental therapeutics for African trypanosomiasis. J Med Chem 2013;56:9861–73.
   PubMed Web of Science ®Google Scholar
• Brochu H, Vermette P. Liposome layers characterized by quartz crystal microbalance measurements and multirelease delivery. Langmuir 2007;23:7679–86.
   PubMed Web of Science ®Google Scholar
• Yang YF, Xie XY, Yang Y, et al. A review on the influences of size and surface charge of liposome on its targeted drug delivery in vivo. Yao Xue Xue Bao 2013;48:1644–50. [In Chinese]
   PubMedGoogle Scholar
• Park JW, Benz CC, Martin FJ. Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol 2004;31:196–205.
   PubMed Web of Science ®Google Scholar
• Jeetah R, Bhaw-Luximon A, Jhurry D. Nanopharmaceutics: phytochemical-based controlled or sustained drug-delivery systems for cancer treatment. J Biomed Nanotechnol 2014;10:1810–40.
   PubMed Web of Science ®Google Scholar
• Haisheng LU, Xiting LI, Jianying Z, et al. Effects of cordycepin on HepG2 and EA.hy926 cells: potential antiproliferative, antimetastatic and anti-angiogenic effects on hepatocellular carcinoma. Oncol Lett 2014;7:1556–62.
   PubMed Web of Science ®Google Scholar
• Yifan L, Rong L, Shenglang Z, et al. Cordycepin induces apoptosis and autophagy in human neuroblastoma SK-N-SH and BE(2)-M17 cells. Oncol Lett 2015;9:2541–7.
   PubMed Web of Science ®Google Scholar
• Jung SM, Park SS, Kim WJ, Moon SK. Ras/ERK1 pathway regulation of p27KIP1-mediated G1-phase cell-cycle arrest in cordycepin-induced inhibition of the proliferation of vascular smooth muscle cells. Eur J Pharmacol 2012;681:15–22.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Kim SK, Choi WS, et al. Cordycepin causes p21WAF1-mediated G2/M cell-cycle arrest by regulating c-Jun N-terminal kinase activation in human bladder cancer cells. Arch Biochem Biophys 2009;490:103–6.
   PubMed Web of Science ®Google Scholar